Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round led by Redhill Capital. Other investors included Ruisheng Equity Investment and Yuanhe Capital. Proceeds will go toward safety validation for its core pipelines, process development and clinical filings, manufacturing plant expansion, and talent recruitment.
Company Background and Technology Platforms
Founded in 2018, Everlife Biomed is focused on the creation of a novel artificial immune exemption microenvironment and clinical translational application platform, to address immune rejection in the field of regenerative medicine and male infertility. The company offers a pluripotent stem-cell editing and directional differentiation platform and an immune exemption cell transplantation protection carrier (universal type) platform.
Pipeline and Future Plans
Its rheumatoid arthritis pipeline, the most advanced, is expected to be readied for clinical filing. The cell transplantation pipeline has completed proof of concept validation against diabetes, with good animal experiment results. For the male azoospermia pipeline, Everlife has developed the prototype of the front-end kit and completed the classification and definition. Owning a 300 square meter R&D and translational laboratory, the company plans to establish a 2,000 square meter manufacturing base upon the funding.-Fineline Info & Tech
